CLPT Quote, Financials, Valuation and Earnings

Semler Scientific has a net margin of -71.02% compared to ClearPoint Neuro's net margin of -732.34%. ClearPoint Neuro's return on equity of -73.69% beat Semler Scientific's return on equity of -23.56%.

ClearPoint Neuro has a consensus price target of $29.00, signalling upside risk potential of 157.55%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 100.45%. Given that ClearPoint Neuro has higher upside potential than Semler Scientific, analysts believe ClearPoint Neuro is more attractive than Semler Scientific.

ClearPoint Neuro has a beta of 0.917, which suggesting that the stock is 8.296% less volatile than S&P 500. In comparison Semler Scientific has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.164%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $8.5M, which are smaller than Semler Scientific quarterly revenues of $8.8M. ClearPoint Neuro's net income of -$6M is higher than Semler Scientific's net income of -$64.7M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Semler Scientific's PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.64x versus 6.07x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -71.02% compared to ClearPoint Neuro's net margin of -2201.34%. ClearPoint Neuro's return on equity of -73.69% beat VolitionRX's return on equity of --.

ClearPoint Neuro has a consensus price target of $29.00, signalling upside risk potential of 157.55%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 282.86%. Given that VolitionRX has higher upside potential than ClearPoint Neuro, analysts believe VolitionRX is more attractive than ClearPoint Neuro.

ClearPoint Neuro has a beta of 0.917, which suggesting that the stock is 8.296% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $8.5M, which are larger than VolitionRX quarterly revenues of $246.4K. ClearPoint Neuro's net income of -$6M is lower than VolitionRX's net income of -$5.4M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.64x versus 52.93x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -71.02% compared to ClearPoint Neuro's net margin of -2828.67%. ClearPoint Neuro's return on equity of -73.69% beat Catheter Precision's return on equity of -137.84%.

ClearPoint Neuro has a consensus price target of $29.00, signalling upside risk potential of 157.55%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 761.7%. Given that Catheter Precision has higher upside potential than ClearPoint Neuro, analysts believe Catheter Precision is more attractive than ClearPoint Neuro.

ClearPoint Neuro has a beta of 0.917, which suggesting that the stock is 8.296% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $8.5M, which are larger than Catheter Precision quarterly revenues of $143K. ClearPoint Neuro's net income of -$6M is lower than Catheter Precision's net income of -$4M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.64x versus 2.67x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -71.02% compared to ClearPoint Neuro's net margin of 0.18%. ClearPoint Neuro's return on equity of -73.69% beat Xtant Medical Holdings's return on equity of -26.62%.

ClearPoint Neuro has a consensus price target of $29.00, signalling upside risk potential of 157.55%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 144.76%. Given that ClearPoint Neuro has higher upside potential than Xtant Medical Holdings, analysts believe ClearPoint Neuro is more attractive than Xtant Medical Holdings.

ClearPoint Neuro has a beta of 0.917, which suggesting that the stock is 8.296% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $8.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. ClearPoint Neuro's net income of -$6M is lower than Xtant Medical Holdings's net income of $58K. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.64x versus 0.80x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.